Bio Medica Laboratories Limited
Bookbuilding IPO · NSE
- Price band
- ₹132 - ₹139
- Lot size
- 1,000 shares
- Issue amount
- ₹52.43 cr
- Total subscription
- 2.31×
- Opens
- 21 May 2026
- Closes
- 25 May 2026
- Allotment
- 26 May 2026
- Listing
- 29 May 2026
Offer at a glance
Issue overview
- Issue size
- 37,72,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,32,000
- Fresh issue
- ₹47.19 cr
- Offer for sale
- ₹5.24 cr
- Registrar
- Skyline Financial Services Private Limited
- Listing exchange
- NSE
- Maximum investment
- ₹1,39,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 91,80,001
- Shares after issue
- 1,25,75,001
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| Retail | 2 | 2,000 | ₹2,78,000 |
| sHNI | 3 | 3,000 | ₹4,17,000 |
| bHNI | 8 | 8,000 | ₹11,12,000 |
Share reservation
Subscription & GMP
Subscription by category
Reported 25 May 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 6 |
| NIB | 0 | 457 |
| RETAIL | 896 | 2,614 |
| HNIs(10L +) | 390 | 35 |
| HNIs (2-10L) | 195 | 422 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 0.5 | 7.98 |
| FIIs | 0 | 7.98 |
| RETAIL | 24.91 | 72.67 |
| HNIs 2+ | 8.13 | 17.82 |
| HNIs 10+ | 16.26 | 16.58 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Nov-25 | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|---|
| EPS | 9.44 | 10.67 | 2.72 | 0.36 |
| ROE | 54.41 | 99.59 | 67.74 | 13.92 |
| ROCE | 23.24 | 48.2 | 29.92 | 10.16 |
| RONW | 0 | 0 | 0 | 0 |
| PRE IPO(PE) | 0 | 13.03 | 0 | 0 |
| POST IPO(PE) | 13.45 | 0 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Bio Medica Laboratories Limited | 0 | 0 | 10.00 | 16.05 | 99.59 | 10.67 |
| Zenotech Laboratories Limited | 0 | 47.95 | 10.00 | 15.76 | 6.01 | 0.92 |
| Shukra Pharmaceuticals Limited | 47.57 | 33.54 | 1.00 | 1.43 | 15.90 | 0.22 |
Company information
Company profile
Bio Medica Laboratories is a pharmaceutical company engaged in manufacturing parenteral formulations for both human and veterinary healthcare segments. The company produces a wide range of ethical drugs, generic medicines, and OTC products, primarily in liquid and dry powder injectable forms. Its portfolio includes 58 liquid injectables and 15 dry powder injectable products available in single-dose and multi-dose formats. Operating on a B2B contract manufacturing model, the company develops customized formulations according to client requirements. Supported by GMP and GLP certifications, Bio Medica runs two manufacturing facilities in Indore, Madhya Pradesh, focusing on quality production and pharmaceutical formulation development.
Strengths
- Diversified Injectable Portfolio: Offers a wide range of liquid and dry powder injectables for various therapeutic needs.
- Strong Contract Manufacturing: B2B-focused model supports customized formulation development for pharmaceutical clients.
- Experienced Management & Workforce: Industry-experienced teams support efficient manufacturing and quality standards.
Risk factors
- Regulatory Compliance Risk: Previous suspension of operations at a manufacturing unit due to non-compliance may affect reputation and business operations.
- Customer Concentration Risk: Dependence on a limited number of clients may impact financial performance if key customers are lost.
- Quality Control & Manufacturing Risk: Product defects or quality issues may lead to litigation, regulatory action, and reputational damage.
Promoters
Mr. Mukesh Mehta
Mr. Pradeep Mehta
Registrar & documents
Lead manager
Narnolia Financial Services Limited
Registrar & contacts
Skyline Financial Services Private Limited
[email protected]Official registrar portal ↗Check allotment status on registrar →Registered office
Plot No. 11B-11C, Sector-E, Sanwer Road Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh, 452015
+91 7314102751
[email protected]Company website ↗Frequently Asked Questions
What is Bio Medica Laboratories IPO GMP today?
As of today, Bio Medica Laboratories IPO Grey Market Premium (GMP) is reported at −₹7 per share. Based on the upper price band of ₹139, the estimated listing price is ₹132 (-5.0% expected discount). Please note that GMP is an unofficial market estimate for sentiment tracking and does not guarantee the actual listing price.
What is the lot size and minimum investment for Bio Medica Laboratories IPO?
The minimum bid lot size for Bio Medica Laboratories IPO is 1,000 shares. At the cut-off price of ₹139 per share, retail investors need a minimum application amount of ₹1,39,000 per lot. Retail applicants can apply for a maximum of 1 lots (up to ₹2,00,000).
When will Bio Medica Laboratories IPO allotment status be announced?
The allotment status for Bio Medica Laboratories IPO is scheduled to be finalized on 26 May 2026. If you applied for the IPO, you can verify whether shares have been allocated to your Demat account through Skyline Financial Services Private Limited's official portal or via BSE/NSE allotment portals.
How can I check Bio Medica Laboratories IPO allotment status online by PAN?
To check Bio Medica Laboratories IPO allotment status: 1) Visit the registrar portal (Skyline Financial Services Private Limited) or the BSE IPO allotment page. 2) Select 'Bio Medica Laboratories Limited' from the company dropdown. 3) Choose 'PAN' as your identification mode and enter your 10-digit Permanent Account Number. 4) Click 'Search' to view your allotted share quantity and application status.
Explore More IPO Analysis & Live Tools
Compare the price band and required investment with company financials and official offer documents. Grey market premium (GMP) figures are indicative market estimates collected from primary market brokers and do not establish the official listing price.